

Patent Docket P0833P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of LASKY, L. ET AL. 08/256,418 Serial No.: 08/256,418 Filed: 11 JULY 1994 For: INHIBITION OF LEUKOCYTE ADHESION	Group Art Unit: 1816 Examiner: GAMBEL, P. <div style="border: 1px solid black; padding: 5px;"><p style="text-align: center;">CERTIFICATE OF MAILING</p><p>I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on</p><p style="text-align: right;">December 26, 1995</p><p style="text-align: right;"><i>Aida A. Miclat</i></p><p style="text-align: right;">Aida A. Miclat</p></div>
--	---

RESPONSE TO RESTRICTION REQUIREMENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

OFFICIAL
FAX CENTER
RECEIVED

Sir:

JUL 1 5 1996

GROUP 1800

A. In an Office Action mailed November 24, 1995 (Paper No. 4), applicants were requested to restrict the present application to one of the inventions represented by Claims 1-14 (Group I), Claims 16-17 (Group II), Claim 19 (Group III), Claims 20-25 (Group IV), and Claims 26-27 (Group V).

Group I (Claims 1-14) is hereby elected for examination purposes.

B. Applicants were further requested to elect a "single disclosed species of a general pathological condition from (A) to (C) [listed in the Office Action] and furthermore of a particular pathological conditions from (D) to (P) [listed in the Office Action] for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable."

Autoimmune diseases (species A) and rheumatoid arthritis (species H - designated as "reactive" arthritis probably due to a typographical error) are elected for the purposes of examination.


08/256,418

Patent Docket P0833P1

C. In the case of restricting the invention to Group I, applicants were also requested to elect a species of the additional therapeutically active compounds listed in claim 9, which may be coadministered with the compounds of claim 1. (Species A), i.e. a "selectin" is hereby elected for examination purposes.

Respectfully submitted,
GENENTECH, INC.

Date: 26 December 1995

By: 
Ginger R. Dreger
Reg. No. 33,055

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-3216
Fax: (415) 952-9881